医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cerveau Technologies, Inc. Signs Research Agreement with Houston Methodist

2017年11月08日 PM11:02
このエントリーをはてなブックマークに追加


 

BOSTON

Cerveau Technologies Inc. today announced an agreement with Houston Methodist Hospital to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

As part of the agreement, Cerveau will contract with Houston Methodist to manufacture and supply the [18F]MK-6240 needed for the initiatives in the greater Houston area as well as support research initiatives at Houston Methodist.

According to Dr. Joseph C. Masdeu, director of Houston Methodist’s Nantz National Alzheimer Center, “this new tau PET tracer could help us better understand the nature of neurodegenerative diseases, such as Alzheimer’s, and monitor the effects of existing and new therapies.”

“Cerveau welcomes this opportunity to work with Houston Methodist researchers to understand the application of MK-6240 and how it may benefit patients with this devastating disease. The collaboration with Houston Methodist will provide access to our pharmaceutical partners in support of various therapy trials as well facilitate novel research at Houston Methodist in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.

About Houston Methodist
The Houston Methodist Neurological Institute advances the discovery of the origins, mechanisms and treatment of neurological disease and provides comprehensive care for patients with disorders and injuries of the brain and spinal cord. The institute houses the practice and research activities of the departments of neurology, neurosurgery, neuroradiology, neurophysiology, and physical medicine and rehabilitation at Houston Methodist.

About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005920/en/

CONTACT

Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
RFhiatt@cerveautechnologies.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用
  • 宝洁公司收购德国达姆施塔特默克集团的消费者健康业务
  • MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
  • Vaxart Announces $5 Million Inavir® Revenue Milestone
  • 和铂医药与科伦博泰开展全球合作,共同开发多个创新全人源抗体药物